Formation of complement-activating particles in aqueous solutions of Taxol: Possible role in hypersensitivity reactions

International Immunopharmacology

Volumn 1, Issue 4, 2001, Pages 721-735

  Szebeni, Janos ^a   Alving, Carl R ^a   Savay, Sandor ^a   Barenholz, Yechezkel ^b   Priev, Aba ^b   Danino, Dganit ^c   Talmon, Yeshayahu ^c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cancer chemotherapy; Cremophor EL; Cryo TEM; Drug allergy; Hypersensitivity reactions; IVIG; Micelles

Indexed keywords

CREMOPHOR; PACLITAXEL;

AQUEOUS SOLUTION; ARTICLE; CANCER CHEMOTHERAPY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CRYSTAL STRUCTURE; CRYSTALLIZATION; FILTRATION; HYPERSENSITIVITY; LIGHT SCATTERING; MICELLE; PARTICLE SIZE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMPLEMENT ACTIVATION; COMPLEMENT MEMBRANE ATTACK COMPLEX; DRUG HYPERSENSITIVITY; GLYCEROL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MICELLES; PACLITAXEL; SOLUTIONS;

EID: 0035098996     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00006-6     Document Type: Article

References (58)

1. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
2. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions
3. Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles
4. Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions
5. A phase I trial of Taxol given as 3-hour infusions every 21 days
6. Acute myocardial infarction following paclitaxel administration for ovarian carcinoma
7. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors
8. Clinical toxicities encountered with paclitaxel (Taxol)
9. Cardiac disturbances during the administration of Taxol
10. Taxol: The first of the taxanes, an important new class of antitumor agents
11. Paclitaxel (Taxol)
12. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration
13. Hypersensitivity reactions from Taxol
14. Paclitaxel hypersensitivity reactions related to bee sting allergy
15. Successful parenteral desensitization to paclitaxel
16. Structure and function of anaphylatoxins
17. Effects of anaphylatoxins on circulation
18. A mechanism of action for anaphylatoxin C3a stimulation of mast cells
19. Pulmonary infiltrates following administration of paclitaxel
20. Hypersensitvity reactions to the taxanes paclitaxel and docetaxel
21. Pharmaceutical properties of paclitaxel and their effects on preparation and administration
22. Properties of cremophor EL micelles probed by fluorescence
23. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells
24. Solubilization and reconstitution of membrane proteins
25. Transmission electron microscopy and light scattering studies on the interaction of a nonionic/anionic surfactant mixture with phosphatidylcholine liposomes
26. Controlled environment vitrification system: An improved sample preparation technique
27. Cryogenic temperature transmission electron microscopy in the study of surfactant systems
28. Quantification of Cremophore EL in human plasma samples using colorimetric dye-binding microassay
29. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
30. Modulation of complement-mediated immune damage by intravenous immune globulin
31. Immunomodulatory effects of intravenous immunoglobulins
32. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes
33. The development and utility of the taxane class of antimicrotubule chemotherapy agents
34. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody
35. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: The causative role of improper dissolution of Cremophor EL
36. Mechanism of anaphylactoid reactions: Improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine
37. Paclitaxel package insert
38. Untersuchungen uber Cremophor EL
39. Paclitaxel formulation as a cause of ethanol intoxication
40. Solute effects on the colloidal and phase behavior of lipid bilayer membranes: Ethanol-dipalmitoylphosphatidylcholine mixtures
41. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal
42. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement
43. Nonionic block polymers: New preparations and review of the mechanism of action
44. Modulation of antigen presentation and host mediators by block copolymer adjuvants
45. The adjuvant activity of nonionic block polymer surfactants: II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers
46. The role of complement in experimental silicosis
47. Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles
48. Enhancement of crystal induced neutrophil responses by opsonisation of calcium pyrophosphate dihydrate crystal
49. Atheroma cholesterol activates complement and aggregates granulocytes: Possible role in ischemic manifestations of atherosclerosis
50. Cholesterol and atheroma lipids activate complement and stimulate granulocytes
51. Mechanism of complement activation by crystalline cholesterol
52. Novel complement inhibitors
53. Predictive capacity of histamine release for the diagnosis of drug allergy
54. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes
55. The role of complement activation in hypersensitivity to pegylated liposomal Doxorubicin (Doxil®)
56. Liposome-induced pulmonary hypertension in pigs: Properties and mechanism of a complement-mediated pseudoallergic reaction